Effect of tirzepatide on weight and metabolism in a multiethnic cohort with and without diabetes.
作者信息
El Ghandour Sara, Akbarpoor Fatemeh, Malik Momina, Kalsekar Madeeha, Vidha Sara, Bhatia Prisha, Al Ghazal Nisrine, Lakshmanan Jeyaseelan, Cherquaoui Rabia, Al Abed Farah, Jomaa Mona, Hajje Georges, Ho Samuel B, Alsaeed Maryam
机构信息
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai, United Arab Emirates.
Clinical Services, Mediclinic Middle East, Dubai, United Arab Emirates.
出版信息
Diabetes Obes Metab. 2025 May;27(5):2891-2895. doi: 10.1111/dom.16287. Epub 2025 Mar 3.
Abstract
摘要
相似文献
1
Effect of tirzepatide on weight and metabolism in a multiethnic cohort with and without diabetes.替尔泊肽对患有和未患糖尿病的多民族队列人群体重及代谢的影响。
Diabetes Obes Metab. 2025 May;27(5):2891-2895. doi: 10.1111/dom.16287. Epub 2025 Mar 3.
2
Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.替尔泊肽在美国无2型糖尿病证据人群中的实际应用及有效性
Diabetes Metab. 2025 May;51(3):101636. doi: 10.1016/j.diabet.2025.101636. Epub 2025 Mar 7.
3
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study.使用替尔泊肽或司美格鲁肽治疗的肥胖成年患者新发2型糖尿病的发病率：一项国际回顾性队列研究的真实世界证据
EClinicalMedicine. 2024 Aug 15;75:102777. doi: 10.1016/j.eclinm.2024.102777. eCollection 2024 Sep.
4
Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity.替尔泊肽对1型糖尿病合并超重或肥胖成人患者体重及血糖控制的影响
Mayo Clin Proc. 2025 Feb;100(2):265-275. doi: 10.1016/j.mayocp.2024.07.006. Epub 2024 Nov 26.
5
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.替尔泊肽在非2型糖尿病个体中的真实世界应用及有效性：来自Optum市场洞察数据库的结果
Diabetes Obes Metab. 2025 May;27(5):2810-2821. doi: 10.1111/dom.16290. Epub 2025 Feb 25.
6
Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States.在美国一家大型三级医疗中心，替尔泊肽在糖尿病和慢性肾脏病患者中的处方实践及疗效
Diabetes Metab Syndr Obes. 2024 Oct 3;17:3621-3628. doi: 10.2147/DMSO.S473319. eCollection 2024.
7
Effects of Semaglutide and Tirzepatide on Bone Metabolism in Type 2 Diabetic Mice.司美格鲁肽和替尔泊肽对2型糖尿病小鼠骨代谢的影响
Pharmaceuticals (Basel). 2024 Dec 9;17(12):1655. doi: 10.3390/ph17121655.
8
Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.替尔泊肽与美国2型糖尿病患者真实世界队列中血糖控制及体重减轻的关联
Diabetes Obes Metab. 2025 Jun;27(6):3453-3463. doi: 10.1111/dom.16372. Epub 2025 Apr 4.
9
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.在SURPASS临床试验项目中接受替尔泊肽治疗的2型糖尿病患者的患者报告结局
Diabetes Ther. 2023 Nov;14(11):1833-1852. doi: 10.1007/s13300-023-01451-z. Epub 2023 Aug 1.
10
Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.替尔泊肽在超重和肥胖 1 型糖尿病成人患者中的疗效和安全性。
Diabetes Technol Ther. 2024 Jun;26(6):367-374. doi: 10.1089/dia.2024.0050. Epub 2024 Apr 18.
本文引用的文献
1
Real world use of tirzepatide in the treatment of type 2 diabetes in an Arab population.阿拉伯人群中利拉鲁肽治疗 2 型糖尿病的真实世界应用。
Diabetes Obes Metab. 2024 Aug;26(8):3381-3391. doi: 10.1111/dom.15680. Epub 2024 May 24.
2
Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study.司美格鲁肽和替尔泊肽治疗胃旁路术后体重复发：一项回顾性队列研究。
Obes Surg. 2024 Apr;34(4):1324-1332. doi: 10.1007/s11695-024-07137-0. Epub 2024 Mar 2.
3
Incretin hormones and type 2 diabetes.肠促胰岛素激素与 2 型糖尿病。
Diabetologia. 2023 Oct;66(10):1780-1795. doi: 10.1007/s00125-023-05956-x. Epub 2023 Jul 11.
4
Prevalence and associated risk factors of overweight and obesity among adult population in Dubai: a population-based cross-sectional survey in Dubai, the United Arab Emirates.阿联酋迪拜成年人超重和肥胖的患病率及相关危险因素：一项基于人群的迪拜横断面调查。
BMJ Open. 2023 Jan 24;13(1):e062053. doi: 10.1136/bmjopen-2022-062053.
5
Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss.抗抑郁药对胰高血糖素样肽-1受体激动剂相关体重减轻的影响。
J Pharm Technol. 2022 Oct;38(5):283-288. doi: 10.1177/87551225221110850. Epub 2022 Jul 29.
6
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.使用双重 GIP/GLP-1 受体激动剂替西帕肽治疗 2 型糖尿病：系统评价和荟萃分析。
Diabetologia. 2022 Aug;65(8):1251-1261. doi: 10.1007/s00125-022-05715-4. Epub 2022 May 17.
7
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.度拉糖肽皮下注射与安慰剂联合滴定的胰岛素甘精胰岛素对 2 型糖尿病患者血糖控制的影响：SURPASS-5 随机临床试验。
JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078.
8
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.司美格鲁肽与甘精胰岛素治疗 2 型糖尿病合并心血管高风险（SURPASS-4）：一项随机、开放标签、平行分组、多中心、3 期临床试验。
Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18.
9
Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年 87 种风险因素的全球负担：2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2.
10
Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over.体重减轻与合并症改善：5%、10%、15%及以上的差异
Curr Obes Rep. 2017 Jun;6(2):187-194. doi: 10.1007/s13679-017-0262-y.
Zotero 插件